FHLC vs XLV

Key Takeaways

• Both FHLC and XLV are passively managed, market-cap-weighted health care ETFs, but they track different indexes with meaningfully different depth and concentration.
• FHLC tracks the MSCI USA IMI Health Care Index with roughly 340–350 holdings, extending exposure into mid- and small-cap names for broader diversification.
• XLV tracks the Health Care Select Sector Index with about 64 large-cap holdings, delivering more concentrated mega-cap exposure and greater liquidity.
• Both funds carry an identical 0.08% expense ratio, so cost is not a differentiator; the real trade-off is diversification versus concentration.
• Top-heavy exposure to LLY, JNJ, and ABBV drives returns in both funds, but the weightings differ at the margins.
• Tickeron AI Verdict: XLV is the current favored ticker, reflecting stronger trend consistency, superior scale and liquidity, and alignment with large-cap health care leadership.

Introduction

Health care remains one of the most structurally relevant sectors in the U.S. equity market, combining defensive cash flows, demographic-driven demand, and a powerful innovation cycle in areas such as GLP-1 weight-loss therapies, oncology, and medical technology. For investors seeking broad sector exposure, FHLC and XLV are two of the most prominent vehicles. While they compete directly for the same investor dollar, they are not identical: one casts a wide net across the full health care investable universe, while the other concentrates on large-cap leaders. Understanding these structural differences is essential for accurate relative positioning.

Fidelity MSCI Health Care Index ETF (FHLC) Overview

FHLC is a passively managed fund that seeks to track the MSCI USA IMI Health Care Index before fees and expenses. The index spans large-, mid-, and small-cap U.S. health care companies, giving the fund roughly 340–350 holdings. Its top positions include LLY, JNJ, ABBV, MRK, and UNH, with the top 10 holdings representing slightly more than half of the portfolio. Sector allocation is effectively 100% health care, with a modest tilt toward smaller-cap names that larger rivals omit. The fund carries an expense ratio of 0.08% and employs a full-replication, market-cap-weighted strategy. Launched in 2013, it offers investors a broader, more diversified take on the sector.

Health Care Select Sector SPDR Fund (XLV) Overview

XLV is a passively managed fund that tracks the Health Care Select Sector Index, which is composed of health care companies drawn from the S&P 500. The fund holds approximately 60–64 large-cap names, making it considerably more concentrated than FHLC. Its largest positions are LLY, JNJ, ABBV, UNH, and MRK, with the top 10 holdings accounting for roughly 60% of assets. The expense ratio is 0.08%, identical to its rival. Launched in 1998, XLV is one of the oldest and largest health care ETFs, commanding substantially more assets under management and trading volume than FHLC, which supports tight spreads and deep liquidity.

Industry and Thematic Backdrop

The health care sector is currently shaped by several powerful, durable forces. The GLP-1 obesity and metabolic-disease market has reshaped pharmaceutical leadership, favoring innovators with blockbuster pipelines. Meanwhile, oncology, immunology, and advanced medical devices continue to attract capital, while demographic aging underpins steady demand for providers, insurers, and diagnostics. Regulatory and policy risk — including drug-pricing scrutiny and the outcome of health policy debates — remains a persistent overhang. Macroeconomic conditions, particularly the path of interest rates, also matter: health care's longer-duration growth names are sensitive to shifts in rate expectations, even as defensive cash flows provide ballast during risk-off periods.

Performance and Positioning Comparison

In recent market cycles, health care returns have been driven disproportionately by a handful of mega-cap names, especially LLY on the strength of its weight-loss franchise. Because XLV concentrates more heavily in these large-cap leaders, it has tended to amplify that leadership when mega-cap momentum is strong. FHLC, by contrast, includes smaller-cap names that add diversification but can dilute the impact of large-cap winners. Both funds exhibit below-market beta relative to the broad S&P 500, but XLV has generally shown a slightly lower beta profile while FHLC offers marginally broader exposure that may be less sensitive to any single holding's pullback. Relative positioning therefore hinges on whether an investor prioritizes concentration in established leaders or broader participation across the sector.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. Explore the AI Screener to refine your own health care search and uncover signals aligned with your strategy.

Tickeron AI Verdict

Based on observable structural factors, Tickeron's AI would currently favor XLV over FHLC. Both funds share identical cost efficiency, but XLV benefits from materially greater scale, deeper liquidity, and a more established track record. Its concentration in large-cap innovators aligns more directly with the momentum currently emanating from GLP-1 and biopharmaceutical leadership, which has been a dominant driver of recent sector performance. While FHLC offers superior breadth and reduced single-name sensitivity, XLV's cleaner large-cap trend profile and tighter relative positioning give it the probabilistic edge in the current environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations